Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. - Wikidata - awgldk - TriplyDB

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.

http://www.wikidata.org/entity/Q37174738

about

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.

http://www.wikidata.org/entity/Q37174738

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Randomised phase III trial of ...... analysis of the ADEBAR study.

@en

Randomised phase III trial of ...... analysis of the ADEBAR study.

@nl

type

label

Randomised phase III trial of ...... analysis of the ADEBAR study.

@en

Randomised phase III trial of ...... analysis of the ADEBAR study.

@nl

prefLabel

Randomised phase III trial of ...... analysis of the ADEBAR study.

@en

Randomised phase III trial of ...... analysis of the ADEBAR study.

@nl

P1433

Q37174738-1201F354-3303-4FCF-B1C3-BE5893DEFE13

P1476

Q37174738-D61BAEDC-4588-4B0B-B6AD-829B4BE4E5D6

P2093

Q37174738-08D06DCD-FA59-4ABB-9985-D951956AEC63

Q37174738-12BCC13D-5FD8-4264-A8F3-B334EDA28A5A

Q37174738-200108E4-2627-4AF3-A9BB-7E29838A37B8

Q37174738-20456B7D-777F-4FE5-8E33-7B82460CC76E

Q37174738-21031565-803B-4A71-BCBB-A8A244A75A0C

Q37174738-63DFA447-1CE4-4D4E-AD61-95E01594AA1B

Q37174738-6DA93766-39FB-4CDC-A0BD-C83146890959

Q37174738-7AA35C40-D3DA-401F-AB4E-816E0CC8FB7D

Q37174738-7D4233AD-A87E-4128-92BB-E6FEF81174C7

Q37174738-8D14F988-83E0-42B9-AA6A-5FF4871F16AE

P2860

Q37174738-0337517B-280C-43D8-BEEA-568B636CEBB9

Q37174738-233C1AA8-B47A-45C0-AF8A-C85598CB8735

Q37174738-277CA8A7-CC62-4860-83C0-821B86FBAC8F

Q37174738-30948B03-2051-4546-AFC0-7E108882C206

Q37174738-3D357911-C59E-4831-9356-CCF3ED87D183

Q37174738-425B18CA-FC7A-4B22-B6BC-14268FA16600

Q37174738-441F653C-7854-437A-B40E-728A2FB6A471

Q37174738-5B3FEECD-36A2-4E83-A576-E1B2F54BED8E

Q37174738-616EFBB7-E7DA-4050-B837-C3B98942CC00

Q37174738-81FDE20E-69CB-4C12-9F0D-2EDA50B7ABA6

P2888

Q37174738-0A77E28B-F312-41D0-AD0B-2D336ADDC71E

P304

Q37174738-8F682CB9-53F2-46A5-999C-B10B447DCE33

P31

Q37174738-51FE67D9-CE54-4578-AEDA-C2B8D72AF798

P356

Q37174738-DD2FA60A-23B2-4025-A2F8-3D6768635A24

P407

Q37174738-4C243B71-7D57-4B36-AE8B-22CF97C00FDE

P433

Q37174738-491BE3F8-8DB5-47C8-8ADB-45FBFE198748

P478

Q37174738-F3626B85-6A65-46B5-85D0-D32704D02BD6

P577

Q37174738-4D9E14F7-BA96-4496-B67D-BE1326C0FFEB

P698

Q37174738-13861FCB-FE8F-45E6-BD06-8A30A1C285E8

P921

Q37174738-9DF5C627-91BF-4F17-B498-D90320C20D12

P932

Q37174738-882D9002-8B04-46A8-988C-ADB94C996821

P356

P1433

British Journal of Cancer

P1476

Randomised phase III trial of ...... analysis of the ADEBAR study.

@en

P2093

A Wischnik

http://www.w3.org/2001/XMLSchema#string

B Rack

http://www.w3.org/2001/XMLSchema#string

C Scholz

http://www.w3.org/2001/XMLSchema#string

D Augustin

http://www.w3.org/2001/XMLSchema#string

J Huober

http://www.w3.org/2001/XMLSchema#string

J Jueckstock

http://www.w3.org/2001/XMLSchema#string

K Annecke

http://www.w3.org/2001/XMLSchema#string

M Kiechle

http://www.w3.org/2001/XMLSchema#string

N Harbeck

http://www.w3.org/2001/XMLSchema#string

T W P Friedl

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment

Adjuvant trastuzumab in HER2-positive breast cancer.

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial

Dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancer

P2888

P304

863-871

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2016.82

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27031854

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4984804

http://www.w3.org/2001/XMLSchema#string